Metastatic Malignant Neoplasm in the Brain

Oncology
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
1 program
1
Single Fraction Stereotactic RadiosurgeryPhase 31 trial
Active Trials
NCT04114981Active Not Recruiting242Est. Mar 2028
Accuray
AccurayMADISON, WI
1 program
1
Laboratory Biomarker AnalysisPhase 11 trial
Active Trials
NCT02716948Completed17Est. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Alliance PharmaceuticalsSingle Fraction Stereotactic Radiosurgery
AccurayLaboratory Biomarker Analysis

Clinical Trials (2)

Total enrollment: 259 patients across 2 trials

NCT04114981Alliance PharmaceuticalsSingle Fraction Stereotactic Radiosurgery

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

Start: Nov 2019Est. completion: Mar 2028242 patients
Phase 3Active Not Recruiting
NCT02716948AccurayLaboratory Biomarker Analysis

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Start: Jun 2016Est. completion: Aug 202117 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space